Response parameters
| . | Dexamethasone* . | Prednisone* . | P . |
|---|---|---|---|
| N (%) . | N (%) . | ||
| pB-ALL prednisone response | |||
| Good | 1494 (93.5) | 1511 (93.6) | .94 |
| Poor | 104 (6.5) | 104 (6.4) | |
| T-ALL prednisone response | |||
| Good | 140 (66.7) | 140 (66.4) | .92 |
| Poor | 74 (33.3) | 71 (33.6) | |
| Remission d33 | |||
| Remission d33 | 1777 (97.8) | 1812 (97.8) | 1.00 |
| No remission d33 | 40 (2.2) | 40 (2.2) | |
| pB-ALL MRD day 33† | |||
| Negative | 580 (47.1) | 565 (43.7) | .00057 |
| Positive <5 × 10−4 | 439 (35.7) | 426 (32.9) | |
| Positive ≥5 × 10−4 | 212 (17.2) | 303 (23.4) | |
| pB-ALL MRD day 78† | |||
| Negative | 970 (78.8) | 1002 (77.3) | .36 |
| Positive <5 × 10−4 | 194 (15.7) | 207 (16.0) | |
| Positive ≥5 × 10−4 | 67 (5.4) | 88 (6.8) | |
| T-ALL MRD day 33† | |||
| Negative | 29 (18.8) | 22 (13.8) | .43 |
| Positive <5 × 10−4 | 41 (26.6) | 41 (25.8) | |
| Positive ≥5 × 10−4 | 84 (54.5) | 96 (60.4) | |
| T-ALL MRD day 78† | |||
| Negative | 78 (50.3) | 70 (43.8) | .43 |
| Positive <5 × 10−4 | 48 (31.0) | 52 (32.5) | |
| Positive ≥5 × 10−4 | 29 (18.7) | 38 (23.8) | |
| MRD risk group† | |||
| MRD-SR | 597 (42.3) | 584 (39.4) | .11 |
| MRD-MR | 717 (50.9) | 771 (52.1) | |
| MRD-HR | 96 (6.8) | 126 (8.5) | |
| Final risk group | |||
| SR-2000 | 577 (31.1) | 561 (30.0) | .77 |
| MR-2000 | 1001 (54.0) | 1026 (55.0) | |
| HR-2000 | 275 (14.8) | 280 (15.0) |
| . | Dexamethasone* . | Prednisone* . | P . |
|---|---|---|---|
| N (%) . | N (%) . | ||
| pB-ALL prednisone response | |||
| Good | 1494 (93.5) | 1511 (93.6) | .94 |
| Poor | 104 (6.5) | 104 (6.4) | |
| T-ALL prednisone response | |||
| Good | 140 (66.7) | 140 (66.4) | .92 |
| Poor | 74 (33.3) | 71 (33.6) | |
| Remission d33 | |||
| Remission d33 | 1777 (97.8) | 1812 (97.8) | 1.00 |
| No remission d33 | 40 (2.2) | 40 (2.2) | |
| pB-ALL MRD day 33† | |||
| Negative | 580 (47.1) | 565 (43.7) | .00057 |
| Positive <5 × 10−4 | 439 (35.7) | 426 (32.9) | |
| Positive ≥5 × 10−4 | 212 (17.2) | 303 (23.4) | |
| pB-ALL MRD day 78† | |||
| Negative | 970 (78.8) | 1002 (77.3) | .36 |
| Positive <5 × 10−4 | 194 (15.7) | 207 (16.0) | |
| Positive ≥5 × 10−4 | 67 (5.4) | 88 (6.8) | |
| T-ALL MRD day 33† | |||
| Negative | 29 (18.8) | 22 (13.8) | .43 |
| Positive <5 × 10−4 | 41 (26.6) | 41 (25.8) | |
| Positive ≥5 × 10−4 | 84 (54.5) | 96 (60.4) | |
| T-ALL MRD day 78† | |||
| Negative | 78 (50.3) | 70 (43.8) | .43 |
| Positive <5 × 10−4 | 48 (31.0) | 52 (32.5) | |
| Positive ≥5 × 10−4 | 29 (18.7) | 38 (23.8) | |
| MRD risk group† | |||
| MRD-SR | 597 (42.3) | 584 (39.4) | .11 |
| MRD-MR | 717 (50.9) | 771 (52.1) | |
| MRD-HR | 96 (6.8) | 126 (8.5) | |
| Final risk group | |||
| SR-2000 | 577 (31.1) | 561 (30.0) | .77 |
| MR-2000 | 1001 (54.0) | 1026 (55.0) | |
| HR-2000 | 275 (14.8) | 280 (15.0) |